A woman with ovarian cancer wearing a coat and green jumper walking down a hospital corridor

ARIEL 4: A study of rucaparib versus chemotherapy in BRCA positive ovarian cancer

Trial at a glance

Open trial

  • Cancer type: Epithelial – high-grade serous and endometrioid | Prevention/BRCA
  • Treatment stage: Recurrence
  • Acronym: Ariel 4

ARIEL4: A study of rucaparib versus chemotherapy in BRCA-positive ovarian, fallopian tube or primary peritoneal cancer

Who can take part

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.


Women may be able to participate if they have: 

  • relapsed, high-grade ovarian, fallopian tube or primary peritoneal cancer
  • had two previous chemotherapy regimens
  • a BRCA1 or BRCA2 mutation
  • no prior treatment with PARP inhibitors or single-agent paclitaxel
  • not required treatment with chemotherapy in the past six months.

This is not an exhaustive list. Women interested in participating in a clinical trial should speak to their own doctor about what other criteria might apply.

About the trial

The aim of the trial is to fully understand the benefits of a PARP inhibitor versus standard chemotherapy for BRCA-positive women who have had two previous treatments.

Drugs involved in this trial:

  • rucaparib, a PARP inhibitor
  • paclitaxel, a standard chemotherapy drug
  • carboplatin or cisplatin, standard chemotherapy drugs.

Women in this trial will be randomised (placed into a treatment group by a computer) into one of three treatment types:

  • rucaparib – oral tablets to be taken twice a day in a 28-day cycle.
  • single-agent paclitaxel – intravenously for women who are platinum-resistant or partially sensitive.
  • single-agent platinum or two chemotherapy drugs – to be given at the doctor's discretion.

If a woman's cancer progresses on the trial and she is receiving one of the chemotherapy drugs there is the option for her to move over onto the rucarparib treatment arm.